{"nct_id":"NCT06112379","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2023-11-14","start_date_type":"ACTUAL","primary_completion_date":"2028-11-20","primary_completion_date_type":"ESTIMATED","completion_date":"2032-09-23","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}